PT  - JOURNAL ARTICLE
AU  - Franchini, Massimo
AU  - Casadevall, Arturo
AU  - Dragotakes, Quigly
AU  - Focosi, Daniele
TI  - Avoided and avoidable deaths with the use of COVID-19 convalescent plasma in Italy during the first two years of pandemic
AID  - 10.1101/2024.08.12.24311864
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.12.24311864
4099  - http://medrxiv.org/content/early/2024/08/12/2024.08.12.24311864.short
4100  - http://medrxiv.org/content/early/2024/08/12/2024.08.12.24311864.full
AB  - Italy was the first western country to be hit by the COVID-19 pandemic and suffered nearly 200,000 deaths so far during the four years of the pandemic. In March 2020, Italy first deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Despite this initial effort, the proportion of COVID-19 patients treated with CCP during the first two years of the pandemic (2020-2021) was very low (approximately 2% of individuals hospitalized for COVID-19). In this study, we estimated the number of actual inpatient lives saved by CCP treatment in Italy using national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimated the potential number of lives saved if CCP had been deployed to 100% of hospitalized patients or used in 15% to 75% of outpatients. According to these models, CCP usage in 2020-2021 saved between 385-1304 lives, but this number would have increased to 17,751-60,079 if 100% of inpatients had been transfused with CCP. Similarly, broader (15-75%) usage in outpatients could have prevented 21,187-190,689 hospitalizations (desaturating hospitals) and 6,144-81,926 deaths. These data have important implications for convalescent plasma use in future infectious disease emergencies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis manuscript generated no new dataset.ARRabsolute risk reductionCCPCOVID-19 convalescent plasmaRRRrelative risk reduction.